Homepage > Urgo products > UrgoStart > UrgoStart

UrgoStart®

product-image
product-image

An innovative dressing combining a polyurethane foam pad with a TLC-NOSF healing matrix.

FEATURES AND CLINICAL BENEFITS

FEATURES BENEFITS
  • Incorporates TLC-NOSF technology
  • Reduces proliferation of MMPs2
  • Incorporates TLC technology
  • Creates a moist wound environment
  • Non-adherent
  • Atraumatic removal
  • Flexible and conformable
  • Assists in good fit on all wound shapes
  • Suitable for cavity wounds
  • Polyurethane Foam/ non-woven contact layer
  • Provides protection to the peri-wound area
  • Offers high-level exudate management
  • Can be cut
  • Will not shed into the wound
  • Seven day wear time (dependent on level of exudate and condition of wound)
  • Reduces need for frequent dressing changes

The efficacy of TLC-NOSF on the reduction of healing time has been demonstrated in double-blind, randomised controlled clinical studies 1,2,3 and by an analysis of observational studies4. The sooner you initiate UrgoStart treatment, the better The healing outcomes5

References

  1. Meaume S, et al. A randomized, controlled, double-blind prospective trial with a Lipido-Colloid Technology-Nano-Oligo Saccharide Factor wound dressing in the local management of venous leg ulcers. Wound Rep Reg. 2012; 20: 4, 500-511.
  2. Edmonds M, Lazaro-Martinez JL, Alfayate-Garcia JM, Martinin J, Petit JM, Rayman G, Lovmann R, Uccioli L, Sauvadet A, Bohbot S, Kerihuel JC, Piaggesi A.  Sucrose octasulfate dressing versus control dressing in patients with neuroischaemic diabetic foot ulcers (Explorer): an international, multicentre, double-blind, randomised, controlled trial.  Lancet Diabetes Endocrinol. 2018 Mar;6(3)186-196.
  3. Meaume S, Truchetet F, Cambazard F et al.  A randomized, controlled, double-blind prospective trial with a Lipido-Colloid Technology-Nano-OligoSaccharide Factor wound dressing in the local management of venous leg ulcers.  Wound Repair Regen. 2012;20:4, 500-511
  4. Munter KC, Meaume S, Augustin M, Senet P, Kerijuel JC.  The reality of routine practice: a pooled data analysis on chronic wounds treated with TLC-NOSF wound dressings.  J Wound care. 2017 Feb; 26 (sup2): S4-S15.  Erratum in: J Wound Care. 2017 Mar 2; 26(3):153
  5. Lazaro et al . Optimal wound closure of diabetic foot ulcers with early initiation of TLC-NOSF treatment: post-hoc analysis of Explorer.JWC VOL 28, NO 6 , June 2019

INDICATIONS

UrgoStart® is indicated for covering and treating the following skin wounds:

  • Leg ulcers
  • Diabetic foot ulcers.
  • Pressure ulcers (bedsores).
  • Other long-lasting or recurrent wounds or wounds at risk of long lasting.

UrgoStart® is intended for use on wounds mainly covered with granulation tissue (red budding tissue in the wound).
UrgoStart® must be secured with a dressing securement system (for example, medical tape, bandage, tubular mesh, or adhesive dressing).

CONTRAINDICATIONS

  • Mucous membrane wounds
  • Malignant wounds
  • Fistula wounds
  • Known hypersensitivity of the patient to one of the TLC or TLC-NOSF dressings, or to carboxymethylcellulose (CMC)

DIRECTIONS FOR USE

instruction-screenshot
instruction-screenshot
instruction-screenshot
instruction-screenshot
  • Clean the wound as per local protocol
  • If antiseptic is first used, carefully rinse the wound with normal sterile saline before applying UrgoStart®
  • Dry the surrounding skin carefully
  • Remove the protective wings
  • Apply the soft-adherent side of UrgoStart® to the wound
  • Secure the dressing in place with a suitable bandage
  • Apply compression bandaging over the dressing when prescribed

PRODUCT OPTIONS

Product Code Product Size Units/Box
100375 6x6cm 10
100376 10x10cm 10
100377 15x20cm 10
10037805 Heel 12x19cm 5

Supplied in boxes of individually packed sterile dressings.

Disclaimer: The product codes published on this website are local reference codes used for ordering, tender, and administrative purposes. They are not the manufacturer's product codes and may differ from the product codes shown on the product label or packaging. The product specifications and intended use remain unchanged.

CLINICAL EVIDENCE

  1. Meaume S, et al. A randomized, controlled, double-blind prospective trial with a Lipido-Colloid Technology-Nano-Oligo Saccharide Factor wound dressing in the local management of venous leg ulcers. Wound Rep Reg. 2012; 20: 4, 500-511.
  2. Edmonds M, Lazaro-Martinez JL, Alfayate-Garcia JM, Martinin J, Petit JM, Rayman G, Lovmann R, Uccioli L, Sauvadet A, Bohbot S, Kerihuel JC, Piaggesi A. Sucrose octasulfate dressing versus control dressing in patients with neuroischaemic diabetic foot ulcers (Explorer): an international, multicentre, double-blind, randomised, controlled trial. Lancet Diabetes Endocrinol. 2018 Mar;6(3) 186-196.
  3. Meaume S, Truchetet F, Cambazard F et al. A randomized, controlled, double-blind prospective trial with a Lipido-Colloid Technology-Nano-OligoSaccharide Factor wound dressing in the local management of venous leg ulcers. Wound Repair Regen. 2012;20:4, 500-511
  4. Munter KC, Meaume S, Augustin M, Senet P, Kerijuel JC. The reality of routine practice: a pooled data analysis on chronic wounds treated with TLC-NOSF wound dressings. J Wound care. 2017 Feb; 26 (2):S4-S15. Erratum in: J Wound Care. 2017 Mar 2; 26(3):153
  5. Lazaro et al . Optimal wound closure of diabetic foot ulcers with early initiation of TLC-NOSF treatment: post-hoc analysis of Explorer.JWC VOL 28, NO 6 , June 2019
  6. Report to the French minister responsible for Social Security and the French Parliament concerning the evolution of French National Health Insurance charges and products for 2014.July 2013.
Page updated on 18 September 2026